Document is current
Any future updates will be listed below
-
Authors
Belbin, Olivia https://orcid.org/0000-0002-6109-6371
Xiao, Mei-Fang
Xu, Desheng
Carmona-Iragui, Maria
Pegueroles, Jordi
Benejam, Bessy
Videla, Laura
Fernández, Susana
Barroeta, Isabel
Nuñez-Llaves, Raúl
Montal, Victor
Vilaplana, Eduard
Altuna, Miren
Clarimón, Jordi
Alcolea, Daniel
Blesa, Rafael
Lleó, Alberto
Worley, Paul F.
Fortea, Juan
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI18/00327, PI17/01019, PI16/01825, PI17/01895, PI18/0335, CP18/00011)
Centro de investigación biomedica en red sobre enfermedades neurodegenerativas (Program 1, Alzheimer Disease)
National Institute on Aging (R35NS097966, R01AG056850-01A1, R21AG056974, R01AG061566)
Departament de Salut, Generalitat de Catalunya (SLT006/17/125, SLT002/16/00099, SLT006/17/00119)
- License Information
-
More Information
Article History
Received: 5 March 2020
Accepted: 10 August 2020
First Online: 17 August 2020
Ethics approval and consent to participate
: The study was approved by the Sant Pau Ethics Committee following the standards for medical research in humans recommended by the Declaration of Helsinki and reported to the Minister of Justice according to the Spanish law for research in people with intellectual disabilities. All participants gave signed, informed consent for the interventions described, inclusion of samples, neuroimaging and demographic data.
: Not applicable.
: OB, AL, JF and DA declare a filed patent application (pending) to the European Patent Office for Markers of synaptopathy neurodegenerative disease (does not relate to data included in this manuscript). MX, DX and PW are co-founders of CogNext.
